Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2018 - 2020)

Summit Therapeutics' Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at $2.1 million for Q3 2020.

  • For Q3 2020, Non-Current Deferred Tax Liability changed N/A year-over-year to $2.1 million; the TTM value through Sep 2020 reached $2.1 million, changed N/A, while the annual FY2019 figure was $2.1 million, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability reached $2.1 million in Q3 2020 per SMMT's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.2 million in Q1 2018 to a low of $2.0 million in Q4 2019.
  • Average Non-Current Deferred Tax Liability over 3 years is $2.4 million, with a median of $2.1 million recorded in 2019.
  • The largest YoY upside for Non-Current Deferred Tax Liability was 33.03% in 2019 against a maximum downside of 33.03% in 2019.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $3.2 million in 2018, then tumbled by 37.44% to $2.0 million in 2019, then increased by 5.1% to $2.1 million in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Non-Current Deferred Tax Liability are $2.1 million (Q3 2020), $2.0 million (Q4 2019), and $2.1 million (Q1 2019).